2. Neurological Disease

Neurological Disease

Neurological Disease

Related Products

PDF 88.0 MB

A range of neurological disorders, including epilepsy and dystonia, may involve dysfunctional intracortical inhibition, and may respond to treatments that modify it. Parkinson’s is a neurodegenerative disease characterized by increased activity of GABA in basal ganglia and the loss of dopamine in nigrostriatum, associated with rigidity, resting tremor, gait with accelerating steps, and fixed inexpressive face. Neurological deficits, along with neuromuscular involvement, are characteristic of mitochondrial disease, and these symptoms can have a dramatic impact on patient quality of life. Neurological features may be manifold, ranging from neural deafness, ataxia, peripheral neuropathy, migraine, seizures, stroke‐like episodes and dementia and depend on the part of the nervous system affected.

Cat. No. Product Name CAS No. Purity Chemical Structure
  • HY-14958
    Pardoprunox 269718-84-5 98%
    Pardoprunox (SLV-308) is a partial dopamine D2 and D3 receptor partial agonist and a serotonin 5-HT1A receptor agonist, with pEC50s of 8, 9.2, and 6.3, respectively.
    Pardoprunox
  • HY-15238
    ST-836 1148156-63-1 98%
    ST-836 is a dopamine receptor ligand; Antiparkinsonian agent.
    ST-836
  • HY-15470
    GW791343 trihydrochloride 309712-55-8 98%
    GW791343 trihydrochloride is a potent human P2X7 receptor negative allosteric modulator (exhibits species-specific activity), produces a non-competitive antagonist effect on human P2X7 receptor, with a pIC50 of 6.9-7.2. GW791343 trihydrochloride can enhance ATP rhythm. GW791343 trihydrochloride can be used in study of neurological disease.
    GW791343 trihydrochloride
  • HY-15543
    CP-809101 479683-64-2 98%
    CP-809101 is a potent and highly selective 5-HT2C receptor agonist, with pEC50s of 9.96, 7.19 and 6.81 M for human 5HT2C, 5HT2B and 5HT2A receptor. CP-809101 inhibits conditioned avoidance responding in rats and antagonizes both PCP (phencyclidine hydrochloride)- and d-amphetamine-induced hyperactivity. CP-809101 also reduces food and nicotine dependence in rats, can be used in studies of antipsychotic and nicotine dependence.
    CP-809101
  • HY-15800
    CZC-25146 hydrochloride 1330003-04-7 98%
    CZC-25146 hydrochloride is a potent LRRK2 inhibitor with IC50 values of 4.76 nM and 6.87 nM for wild-type LRRK2 and G2019S LRRK2, respectively. CZC-25146 hydrochloride inhibits PLK4, GAK, TNK1, CAMKK2 and PIP4K2C as well. CZC-25146 hydrochloride prevents mutant LRRK2-induced injury of neurons in vitro. CZC-25146 hydrochloride exhibits relatively favorable pharmacokinetic properties in mice. CZC-25146 hydrochloride can increase normal α-1-antitrypsin (AAT) secretion and reduce inflammatory cytokines. CZC-25146 hydrochloride can be used to research Parkinson's disease and liver diseases.
    CZC-25146 hydrochloride
  • HY-16923
    Crobenetine 221019-25-6 98%
    Crobenetine (BIII-890), a benzomorphan derivative, is a potent, selective, and highly use-dependent Na+ channel blocker. Crobenetine displaces [3H]BTX from site 2 of the Na+ channel (IC50=49 nM) in rat brain synaptosomes, yet exhibits only low binding affinity for other receptors and ion channels. Crobenetine protects brain tissue from the deleterious effects of focal cerebral ischemia in rodents.
    Crobenetine
  • HY-17033
    Rocuronium 143558-00-3 98%
    Rocuronium (Org-9426) is an aminosteroid non-depolarizing neuromuscular blocker or muscle relaxant used in modern anaesthesia.
    Rocuronium
  • HY-17457
    Levalbuterol tartrate 661464-94-4 98%
    Levosalbutamol tartrate(levalbuterol) is the R-enantiomer of the short-acting β2-adrenergic receptor agonist salbutamol.
    Levalbuterol tartrate
  • HY-18039
    WAY-361789 1040718-40-8 98%
    WAY-361789 (SEN15924) is an orally active agonist for α7 nicotinic acetylcholine receptor (α7 nAChR) with an EC50 of 0.18 μM. WAY-361789 improves the cognitive function, exhibits potential in ameliorating Alzheimer’s Disease and schizophrenia.
    WAY-361789
  • HY-18112
    AZ-4217 1383846-83-0 98%
    AZ-4217 is an inhibitor for β-site amyloid precursor protein cleavage enzyme 1 (BACE1), with IC50 of 160 pM in human SH-SY5Y cells. AZ-4217 reduces amyloid deposition in Tg2576 mouse models, and is used for Alzheimer’s Disease research.
    AZ-4217
  • HY-18297
    ASK1-IN-5 1124381-69-6 98%
    ASK1-IN-5 (S-99) is an inhibitor of apoptosis signal-regulated kinase 1 (ASK1) and is useful in the study of autoimmune and neurodegenerative diseases.
    ASK1-IN-5
  • HY-18332
    Amitifadine 410074-73-6 98%
    Amitifadine (DOV-21947) is an antidepressant drug candidate that functions as a triple reuptake inhibitor, targeting the reuptake of serotonin, norepinephrine, and dopamine, and has been shown to decrease binge drinking and alleviate negative emotions in animal models.
    Amitifadine
  • HY-19005
    GYKI-32887 78463-86-2 98%
    GYKI-32887 is a dopaminergic agonist that can reduce the motor activity levels in rats.
    GYKI-32887
  • HY-19010
    BMY-25368 86134-80-7 98%
    BMY-25368 (SKF 94482) is a histamine H2 receptor antagonist that acts as a gastric acid secretion inhibitor. BMY-25368 competitively antagonizes gastric secretion stimulated by histamine and also antagonizes gastric secretion stimulated by Pentagastrin (HY-A0261), Bethanechol (HY-B0406), and food.
    BMY-25368
  • HY-19036
    SDZ NVI 085 104195-17-7 98%
    SDZ NVI 085 is a compound with CNS stimulatory effects, primarily through the α1-adrenoceptor subtype, with anti-cataplexy and anti-stroke activities. SDZ NVI 085 also has a significant alertness effect and can be used to study other types of excessive sleepiness.
    SDZ NVI 085
  • HY-19065
    Ru-32514 90807-98-0 98%
    Ru-32514 is an agonist of benzodiazepine receptor.
    Ru-32514
  • HY-19082
    Y-23684 118288-67-8 98%
    Y-23684 is a partial agonist of benzodiazepine receptor (BZR) with anticonvulsant and anxiolytic activities. Y-23684 can be used in the research of treatment of anxiety disorders.
    Y-23684
  • HY-19100
    ADX-10061 128022-68-4 98%
    ADX-10061 (compound NNC 687) is a dopamine D1 receptor antagonist with the Ki values of 9.1 nM, 5.8 nM, > 10 000 nM and 355 nM for adenylyl cyclase, D1, D2 and 5-HT2 receptor, respectively. ADX-10061 can be used for study of schizophrenia.
    ADX-10061
  • HY-19136
    WAY-100289 136013-69-9 98%
    WAY-100289 is an orally active antagonist for 5-HT3 receptor, that exhibits high affinity to the isolated rat vagus nerves with pA2 of 8.9. WAY-100289 inhibits the Bezold-Jarisch reflex in anesthetized and awake rats.
    WAY-100289
  • HY-19146
    CL-275838 115931-65-2 98%
    CL-275838 is a memory-enhancing agent, also with potent antidepressant activities.
    CL-275838
Cat. No. Product Name / Synonyms Application Reactivity